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ABSTRACT 
 
Human umbilical cord blood (CB) hematopoietic stem cells (HSCs) have well 
established applications for cellular therapy.  Current protocols for isolating HSCs from 
bone marrow or cord select for CD34+ cells, however some CD34- populations have 
recently been shown to also contain strong HSC activity.  Thus the positive selection of 
HSCs based on cell surface markers remains controversial.  However, it is clear from the 
literature that differentiated hematopoietic cells (lineage positive, Lin+), representing the 
vast majority (>90%) of most blood populations, contain no long-term reconstitution 
potential.  Thus Viacell Inc. (Worcester, MA) expands and enriches its populations of 
cells containing HSCs by removing only those Lin+ cells known not to contain HSCs.  
This is accomplished on two separation columns (post-sep-1, and post-sep-2) (separated 
by 7 days of cell growth) that contain a variety of antibodies to known differentiation 
surface markers.  Although this process strongly enriches functional HCSs, these 
primitive cell populations remain biochemically uncharacterized.   
Because HSC populations containing long chromosomal telomeres and high 
telomerase activity (which helps maintain telomeres) have been shown to display the 
strongest long-term reconstitution potential, the purpose of this thesis was to investigate 
these two parameters in selected samples of Viacell’s ex vivo amplification procedure.  
Two specific hypotheses were tested:  1. the removal of Lin+ cells will appear to increase 
the telomerase activity and telomere lengths in the remaining cell population, and 2. these 
two parameters will decrease upon hematopoietic cell differentiation and proliferation.  
Telomerase activity was assayed using a telomeric repeat amplication protocol (TRAP), 
and normalized relative to a cancer cell line positive control.  Relative to fresh cord 
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blood, telomerase activity was found to increase significantly in post-sep-1 (from 8.5 ± 
1.5% to 76.2 ± 4.9%, p = 0.0001, n = 5) and post-sep-2 (8.5 ± 1.5% to 111.3 ± 4.9%, p = 
0.0001, n = 5) fractions following the removal of Lin+ cells.  This increase was found to 
be highly reproducible, showing very low intra-cord and inter-cord variability.   Telomere 
lengths were assayed using a telomere length assay (TLA).  Relative to fresh cord blood, 
telomere lengths increased significantly in post-sep-1 (from 10 to 12 kb, n = 2) and post-
sep-2 (from 10 to 14 kb, p = 0.001, n = 2) fractions.  These apparent increases likely 
result from the direct removal of cells low in telomerase activity with short telomeres 
since the Lin+ cells from the post-sep-1 column were found to contain relatively low 
telomerase activity (32.1 ± 15%, p = 0.001, n = 2) and short telomeres (7.5 kb, p = 
0.001), which supports our first hypothesis.  Finally, we show that telomerase activity 
and telomere lengths decreased in Day-14 cells (expanded and differentiated 14 days) 
relative to post-sep-2 (from 111.8 ± 19.6% to 54 ± 21.2%, p = 0.001, n = 3 for the TRAP, 
and from 14 kb to 9 kb, p = 0.0001, n = 2 for the TLA).  Those two parameters also 
decreased in pre-sep-3 cells (terminally differentiated by treatment with All Trans 
Retinoic Acid for 14 days) relative to post-sep-2 (from 111.3 ± 4.9% to 14.8 ± 1.7%, p = 
0.0001, n = 6 for the TRAP, and from 14 kb to 7.5 kb, p = 0.001 for the TLA), supporting 
our second hypothesis.  Telomerase activity was found to not directly correlate with 
CD34+CD38- content, supporting recent observations that a significant portion of HSCs 
reside outside this population. 
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BACKGROUND 
 
 
 
Hematopoietic Stem Cells 
 Hematopoietic stem cells (HSCs) (fig. 1) are multipotent cells with the ability to 
reconstitute all hematopoietic lineages, including the formation of additional stem cells 
(Quesenberry et al., 1998).  Hematopoiesis is a complex biological process in which  
 
 
 
   
 
 
 
                                
 
 Figure 1.  Scanning Electron Micrograph of  HSCs in Bone Marrow 
                                                        (McLaren, 2001) 
                                                                  
HSCs differentiate by two basic pathways to give rise to lymphoid, myeloid and erythroid 
cell lineages (fig. 2).  Because of this potential, HSCs are used for cell therapy following 
chemotherapy or radiation therapy.   
 
How are HSCs Identified? 
 
What constitutes hematopoietic stem cells has been the subject of intense debate 
in the literature.  The cell surface marker sialomucin-like adhesion molecule CD34 is 
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frequently used as a convenient marker for HSCs (Civin et al., 1985; Andrews et al., 
1989).  The CD34 antigen is expressed on 1%-3% of all mononuclear bone marrow (BM) 
cells, and 1% of all nucleated cells in cord blood from full term deliveries (Civin and 
Gore, 1993; Kinniburgh and Russell, 1993).  However, the CD34+ fraction lacking the B-
lymphoid marker CD38 in umbilical cord blood accounts for 4% of the CD34+ fraction 
compared to only 1% in bone marrow, indicating that umbilical cord blood may be 
relatively enriched in stem cells (Cardoso et al., 1993). CD34 is found on both HSCs and 
early committed progenitors (Krause et al., 1996).  Using the most definitive assays to 
date for HSC function, CD34+ cells have been shown to possess colony forming potential 
in 
 
 
in vitro cultures (Sutherland et al., 1989) and to allow the differentiation of blood cell 
lineages in immunocompromised mice (Bhatia et al., 1997).  Moreover, CD34 plays an  
important role in the formation of progenitor cells in both fetal and adult hematopoiesis 
Figure 2: Differentiation of Hematopoietic Stem Sells from Bone Marrow (NIH, 2001) 
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(Quensberry et al., 1998).   
   In addition to the CD34 marker, Ziegler et al (1999) showed that the vascular 
endothelial growth factor receptor 2 (VEGFR2, also known as kinase domain receptor, 
KDR) is a positive functional HSC marker that distinguishes HSCs from progenitors. 
HCSs were located in the CD34+KDR+ cell fraction, whereas lineage-committed 
hematopoietic progenitor cells (HPCs) are restricted to the CD34+KDR- subset.  
Several additional cell surface markers allow the distinction of HSCs from their 
more specialized offspring.  Terstappen et al (1991) showed that lineage commitment of 
the CD34+ cells into the erythroid lineage could be assessed by the coexpression of high 
levels of the CD71 antigen, the myeloid lineage by coexpression of the CD33 antigen, 
and the B-lymphoid lineage by coexpression of the CD10 and CD38 antigens.  The 
CD34+CD38+ cell populations are known to be heterogeneous in morphology and contain 
myeloblasts, erythroblasts, and lymphoblasts.  In contrast, the CD34+CD38- cell 
population lacks differentiation markers and are homogeneous primitive blast cells by 
morphology, and has the ability to form primitive colonies (Terstappen et al., 1991).  
HLA-DR is absent or is expressed at low levels on adult HSCs, but is present on fetal and 
neonatal hematopoietic stem/ progenitor cells (Lansdorp et al., 1993).  Based on the 
results of long-term culture-initiating cells (LTC-IC) and various other assays, human 
HSCs are also frequently defined as Lin-CD34+DR- (Srour et al., 1993; Galy et al., 1998; 
Ogawa et al., 1996; Cashman et al., 1997; Hogan et al., 1997). Table 1 lists some of the 
known phenotypes of adult hematopoietic stem and progenitor cells.  
However, CD34 is not a perfect marker for HSCs.  Recent studies in murine and 
human models have indicated that CD34- HSCs possess engraftment potential and 
distinct HSC characteristics (Dao and Nolta, 2000; Ogawa, 2002). These studies 
challenge the dogma that HSC are exclusively found in the CD34+ subset, and question 
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whether primitive HSCs are CD34+ or CD34- (Engelhardt et al., 2002). Recent data reveal 
the presence of Lin-CD34- subpopulations with long-term reconstitution potential, and 
 
 
 
 
 
 
 
 
 
 
suggest the absence of long-term reconstitution potential in the CD34+ fraction.  
However, this data contrasts with a variety of human transplant experiments (Goodell et 
al., 1996; 1999; Dao and Nolta, 2000; Andrews et al., 2000; Ogawa, 2002).  Moreover, 
cord blood (CB) Lin-CD34- cells have been shown to generate CD34+ HSCs when 
cultured in the presence of a murine BM stromal cell line which suggests that Lin-CD34- 
cells possess extensive potential for generation of CD34+ HSCs in vitro.  These derived 
CD34+ cells produce colony forming units (CFU) and LTC-IC with multilineage 
differentiation potential, all of which are characteristics of HSCs (Summers et al., 2001). 
In addition, the demonstration of CD34- HSCs in NOD/SCID mice (Galy et al., 1998; 
Sato et al., 1999), and the development of CD34+ cells from cultures of initially CD34- 
HSCs (Sato et al., 1999; Ando et al., 2000; Tajima et al., 2000; 2001; Ogawa, 2002) 
suggest that HSC activity exists within the murine and human Lin-CD34- population, 
Stem Cells Progenitor Cells 
CD34+ CD34+ 
KDR+ KDR- 
AC133+ AC133+ 
Lin- CD33+, CD54+, CD7+, CD19+, CD24+(3%-30%) 
 CD9+, CD18+, CD29+, CD31+, CD38+, CD44+ 
CD45-RAlo (>70%) CD45+ 
Thy-1+ Thy-1+ (5%-25%) 
HLA-DR- HLA-DR+ 
c-kit+ kit+ (70%-80%) 
Flk-2+ Flk-2+ (20%-50%) 
MDR1hi MDR1lo 
Rhodaminedull Rhodaminebright 
Table 1. Phenotypes of Adult Human Hematopoietic Stem and Progenitor Cells 
(Quesenberry et al., 1998). 
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raising doubts on the frequent practice of using the positive selection of CD34+ cells for 
cell therapy. 
ViaCell defines their HSCs obtained from umbilical cord blood (UCB) as 
CD34+CD38-Lin-. However, their negative selection process (which removes >90% of 
Lin+ cells) enriches a combination of CD34-, CD34+, and primitive cells. Thus, ViaCell 
believes that their process of isolating HSCs by removing only those cells (Lin+) known 
not to be HSCs is superior to the standard art of CD34 positive selection. 
 
Umbilical Cord Blood HSCs 
 
In 1974, Knudtzon showed that relatively mature hematopietic progenitor cells 
(HPCs) are present in human UCB.  Eight years later, Nakahata and Ogawa (1982) 
documented the presence of primitive HPCs in UCB. Later, Broxmeyer et al (1989) 
provided experimental evidence that UCB is a rich source of hematopietic stem/ 
progenitor cells (HSPCs).  Because of these studies and others, UCB has gained 
tremendous acceptance over the last decade as a potential source of transplantable stem 
cells.  Gluckman et al (1989) reported the first human HSC transplant in which UCB was 
used instead of BM as the source of HSCs.   
Studies have shown that significant functional differences exist between HSCs 
and HSPCs from UCB versus adult BM.  UCB contains a higher proportion of primitive 
HSCs than adult BM and peripheral blood (PB) (Lansdorp et al., 1993; Hirao et al., 1994; 
Traycoff et al., 1995).  HSCs derived from UCB possess higher proliferation and 
expansion potential than BM and PB HSCs (Vaziri et al., 1994; Cairo et al., 1997; 
Traycoff et al., 1995; Hao et al., 1995).  Unlike BM and PB, UCB cells appear to be in a 
relatively naïve immunological state (Johnson et al., 1998), which is thought to result in  
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reduced incidences of graft versus host disease (GVHD) in allogeneic transplants (Rocha 
et al., 2000).  UCB provides other advantages as a source of HSCs in its ability to be 
banked and stored following birth (Rubeinstein et al., 1993), the lower potential risk of 
transmissible infectious diseases, the absence of donor attrition, the absence of donor 
collection risks, and the ability to develop high definition donor pools to better target 
ethnic and racial minorities who are vastly under represented in current BM registries 
(Wagner et al., 1998). 
 
Ex- vivo Expansion of Hematopoietic Stem Cells 
 
  
Although cord blood is an attractive alternative to BM or PB as a source of 
transplantable hematopoietic tissue, a major limitation is the relatively low cell number 
available, which is believed to contribute to delayed engraftment in CB transplantations 
as compared to BM or PB transplantations.  The time to engraftment has been reported to 
be inversely related to the cell dose given, suggesting that the injection of more HSCs 
might lead to accelerated engraftment (Kurtzberg et al., 1996; Rubeinstein et al., 1998).  
Further, because of the low overall HSC cell number in CB there may be enough HSCs 
from one cord to reconstitute one child, but the ability to fully reconstitute an adult 
requires ex-vivo expansion (Piacibello et al., 1998). 
The in vitro expansion of HSCs depends on both intrinsic (biological properties of 
the cell subpopulation) and extrinsic (cytokines and culture conditions) properties 
including such variables as non-HSC cell types, cytokines that form the 
microenvironment, the type of culture medium, the medium change schedule, 
temperature, the presence or absence of serum, etc. (Mayani and Lansorp, 1998).  The 
most common current expansion technology involves CD34 enrichment (Kohler et al., 
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1999).  This type of enrichment displays optimum results when a combination of three 
growth factors: stem cell factor (SCF), FLT-3L and IL-3 is included (Kohler et al., 1999).  
However, in other experiments, the best results were obtained using combinations of FL, 
thrombopoietin (Tpo), KL and IL-6 (Piacibello et al., 1998; Gilmore et al., 2000). 
 
ViaCell: Company Information and Research Interests 
 
 
ViaCell, Inc. is a new cellular medicine company merged from two previous 
companies: Viacord, Inc. in Boston, Massachusetts, and t. Breeders, Inc. in Worcester, 
Massachusetts.  Viacord specializes in storing cord blood stem cells from the umbilical 
cords of newborns for future use within that family.  T. Breeders is a biotechnology 
company with proprietary technology for expanding UCB derived HSCs.  The goal of the 
new combined biotechnology company is to use its high quality cord blood banking 
service and patented stem cell expansion technology to develop a premier cellular 
pharmaceutical company to provide high quality cellular medicines for the treatment of 
human diseases, such as cancer, certain genetic disorders, organ transplant tolerance, and 
autoimmune diseases (Craig, 2000; ViaCell, Inc. Annual Report, 2001).  ViaCell has an 
Investigational New Drug (IND) application approved by the FDA and is initiating a 
Phase I clinical trial for testing its proprietary selective amplification technology. 
 
Selective Clonogenic Amplification TM 
          ViaCell, Inc. has developed a patented ex-vivo system called Selective 
Clonogenic Amplification TM (SCA), to select and amplify a population of cells 
containing HSCs.  SCA enables simultaneous selection and amplification of stem cells 
from BM, mobilized PB, or CB through the use of highly specific markers on 
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differentiated cells (t. Breeders, 2000).  This method utilizes the “negative selection 
separation” of HPSCs.  This separation method, as shown in figure 3, uses a cocktail of  
 
 
 
antibodies that bind to mature and differentiated cell surface markers from the 
mononuclear cell population, tagging them for removal using magnetic beads. This 
separation results in a subpopulation of cord blood mononuclear cells that ViaCell terms  
CD34+CD38-Lin- cells, but which also contain CD34- cells, both of which are believed to 
contain stem cells (Hao et al., 1995).  Lin- cells are negative for the differentiated markers 
CD2, CD3, CD14, CD16, CD19, CD24, CD56, CD66b, and Gly A, which are expressed 
on the surface of mature red blood cells, monocytes, natural killer cells, and T cells.  
After amplification of UCB-derived HSCs, ViaCell believes that these new cells now 
have the capability of reconstituting a 200-kg person(s), instead of a 20-kg child before 
Figure 3. ‘Negative Selection Separation’ to Remove Unwanted Differentiated Cells 
                (Zimmerman, 1998) 
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amplification; Phase I clinical trials are underway to prove this. ViaCell’s 14-day 
expansion process includes the following steps as shown in figure 4: 
 
 
 
 
Telomerase Activity and Telomere Length in Hematopoietic Stem Cells 
 
Telomeres, the nucleoprotein complex at the ends of eukaryotic chromosomes, are 
characterized by the presence of a large number of highly conserved tandem repeats of G-
rich DNA (Blackburn, 1991).  In humans and other vertebrates, the telomeric sequence 
contains TTAGGG repeats (Moyzis et al., 1988).  Studies in various species have shown 
that telomeres mediate important chromosome/nuclear matrix interactions (Mathog et al., 
1984), protect encoding DNA from enzymatic breakdown (Sandell and Zakian, 1993), 
may exert effects on regional subtelomeric gene transcription (Levis et al., 1985; 
Gottschling et al., 1990), interact critically with cell-cycle regulatory mechanisms 
(Sandell and Zakian, 1993; Weinert and Hartwell, 1988; Schiestl et al., 1989), and  
Figure 4. ViaCell’s UCB Cell Selection and Amplification Process Time Course 
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prevent chromosome dicentric fusion and other chromosomal aberrations (de Lenge and 
DePinho, 1999; Smith and Blackburn, 1999).  The length of telomeres is remarkably 
variable because of the variability in the number of TTAGGG repeats (de Lenge et al., 
1990).  Telomere lengths show wide inter-individual variation, and they also vary among 
cells in the same tissue and among chromosomes in the same cell (Blackburn, 2000).   
 
 
 
 
 
 
 
 
 
 
 
Table 2 shows average telomere lengths in various human cell types.  Due to the inability 
of DNA polymerase to replicate the ends of eukaryotic chromosomes completely 
(Watson, 1972; Olovnikov, 1973), each cell division results in a loss of 50 bp to 200 bp 
of telomere repeats in normal human somatic cells (Smith and deLange, 2000; Harley et 
al., 1990; de Lange et al., 1990; Allsopp et al., 1992; Vaziri et al., 1994; Chang and 
Harley, 1995).  If a minimal telomere length is essential for chromosomal integrity and 
replication, short telomere lengths could limit the replicative lifespan of cells. Hence,  
 
 
 Table 2: Average Telomere Lengths in Various Human Cell Types 
Allsopp et al., 1992 6- 6.8 Fibroblasts Short 
Engelhardt et al., 1997 7.4 Peripheral Blood 
Engelhardt et al., 1997 7.6 Bone Marrow 
Weng et al., 1997 8- 9 B Lymphocytes 
(Naive & Memory) 
Medium 
Engelhardt et al., 1997 10.4 Cord Blood (CD34+) 
Engelhardt et al., 1997 11  Fetal Liver (CD34+)  Long 
Reference     Telomere Length 
(Kb) 
Source Size 
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telomere shortening is considered a molecular or “mitotic clock” that counts the number 
of cell divisions and determines the onset of cellular senescence (Harley, 1991; Shay et 
al., 1996).  
In contrast to differentiated cells, cells with essentially unlimited replicative 
potential such as reproductive cells, immortal cell lines and cancer tissues have stable 
telomeres (de Lange et al., 1990; Hastie and Dunlop, 1990; Allsopp et al., 1992).  The 
maintenance of telomere lengths in these cells is highly correlated with the presence of 
telomerase, a ribonucleoprotein enzyme which synthesizes telomeric repeats de novo 
(Greider an Blackburn, 1985; Morin, 1989; Harley, 1991; Counter et al., 1994; Kim et al., 
1994).  Studies have shown that telomerase activation is necessary for stabilizing 
telomere lengths, thereby maintaining the replicative capacity of self-renewing cells such 
as germ line cells, tumor cells, and possibly stem cells of various tissue types (Harley et 
al., 1990; 1991; Allsopp et al., 1992). 
  Sensitive assays for telomerase (Kim et al., 1994) have revealed low but 
detectable activity in human hematopoietic cells (Counter et al., 1995) and in highly 
enriched human hematopoietic progenitors (Shay, 1995; Lansdorp et al., 1996).  This 
basal level of telomerase activity was found to increase in very early hematopoietic 
progenitors when they were “stimulated” with growth factors (Engelhardt et al., 1997).  
Interestingly, the average telomere lengths of primitive HSCs decrease upon proliferation 
despite thier having detectable telomerase activity (Vaziri et al., 1994).  Studies carried 
out in peripheral blood cells as a function of age (Hastie and Dunlop, 1990; Vaziri et al., 
1994) and in cultures of hematopoietic cells (Vaziri et al., 1994) suggest that although 
these cells contain detectable telomerase, this telomerase activity is not sufficient to 
prevent the telomere shortening induced by cell division. 
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 The level of telomerase activity is different in human HSCs and their 
differentiated progeny (Counter et al., 1995; Hiyama et al., 1995; Chiu et al., 1996; 
Zhang et al., 1996) as depicted in figure 5.  Primitive HSCs are likely to be quiescent 
most of the time, and thus these cells exhibit a low level of telomerase activity and no 
proliferation-induced shortening.  However, upon stimulation with cytokines, which 
cause the cells to proliferate, telomerase activity appears to be upregulated in the HSC’s 
immediate progeny, which may help slow down the rate of telomere erosion induced by 
cell division.  The more mature cells then become quiescent again and downregulate 
telomerase activity upon differentiation (Lansdorp et al., 1996; Engelhardt et al., 1997; 
Yui et al., 1998).  Supporting the above observations, Vaziri and Benchimol (1998), also 
found a low basal level of telomerase activity in the most primitive quiescent HSCs (with 
a CD34+CD71LowCD45+RAlow phenotype), and in the more mature CD34+ cells, and an 
upregulation of telomerase activity in the cycling CD34+CD71+ progenitors.  Thus 
telomerase activity appears to correlate best with CD34+ cell cycling than simply the 
presence of CD34.  Whether low, but detectable telomerase activity in the primitive 
HSCs is related to their functional “self-renewal potential” is currently under 
investigation. 
 What is the physiological basis of this upregulation and downregulation of 
telomerase activity?  Telomerase activity is increased when the cells are in the G1, S, and 
G2+M phases of the cell cycle, but is repressed when such cells enter G0 due to growth 
factor deprivation or differentiation (Zhang et al., 1996; Holt et al., 1996a; Engelhardt et 
al., 1997).  These observations lead to the important concept that one major factor 
influencing the level of telomerase activity observed in a population of telomerase-
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competent cells is the fraction of cells undergoing proliferation.  If most of the cells are in 
G0, telomerase activity will be very low, while if most are dividing the telomerase  
 
 
activity will be much higher (Shay et al., 1996).  Telomerase-positive immortal cells 
express telomerase activity at each stage of the cell cycle.  As cells exit the cell cycle and 
enter a state of nondivision (G0) via quiescence, senescence, or differentiation, telomerase 
activity is dramatically decreased until it becomes virtually undetectable. However, the 
process is reversible.  Quiescent cells are able to reenter the cell cycle and reexpress 
telomerase activity (Holt et al., 1996b). 
 
 
Figure 5. Telomerase Activity in Normal Hematopoietic Cell Populations. 
                 (Ohyashiki et al., 2002) 
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        Figure 6.  Model for the Repression of Telomerase Activity in Cells that Exit the Cell Cycle. 
                           (Holt et al., 1996b) 
 
 
 Recent studies have suggested that telomerase activity in human BM and PB 
could be almost exclusively assigned to the hematopoietic progenitor cell fraction 
expressing the CD34 antigen (Hohaus et al., 1997).  CD34+ cells lacking co-expression of 
myeloid marker CD33 demonstrated higher levels of telomerase than myeloid committed 
CD34+CD33+ cells (Hohaus et al., 1997).  Hohaus et al (1997) suggested that at least a 
portion of the hematopoietic stem/ progenitor cell fraction expresses telomerase, and 
downregulates its expression during differentiation.  Further, ex-vivo expansion of human 
CD34+ cells derived from BM, fetal liver (FL), PB and CB in the presence of a cytokine 
combination (KL, IL-3, IL-6, erythropoietin, granulocyte colony-stimulating factor and 
stem cell factor) showed upregulation of telomerase activity which peaked after one week 
of expansion, and sharply declined during the second week, decreasing to baseline levels 
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after 3-4 weeks (Engelhardt et al., 1997).  Engelhardt et al also showed that CD34+ cells 
from CB display long telomeres relative to BM and PB.  During four weeks of ex-vivo 
expansion of CD34+ cells, telomere length progressively shortened, with the smallest 
telomere lengths detected in highly differentiated cells after 3-4 weeks of expansion 
(Engelhardt et al., 1997).  These results suggest that cell populations high in telomerase 
activity initially show increased telomere lengths, then shortening upon prolonged 
expansion.             
 Maintenance of telomere length is of immense significance in cell therapy 
experiments since studies have shown that long telomere lengths result in improved graft 
survivability (Lansdorp et al., 1997; Notaro et al., 1997; Vaziri and Benchimol, 1998).  
Moreover, increased telomerase activity in hematopoietic cells is associated with self-
renewal potential (Morrision et al., 1996).  Because of these correlations, ViaCell has an 
interest in analyzing telomerase activity and telomere lengths throughout their entire 
selection/ amplification protocol. 
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PROJECT PURPOSE 
 
The purpose of this project was to test two hypotheses that 1. telomerase activity 
and telomere lengths increase upon removal of differentiated cells, and 2. decrease upon 
differentiation of hematopoietic cells.  To test these hypotheses, telomerase activity and 
telomere lengths were assayed in each of ViaCell’s amplification fractions, which 
comprised human umbilical cord blood cell samples obtained at various intervals of a 
two-week ex vivo stem cell amplification process. Telomerase activity was quantified by 
a TRAP assay, which was found to produce low inter-cord and intra-cord variability. We 
also analyzed the quantitation data by analysis of variance (ANOVA).   
 In the work presented here, I show that telomerase activity is apparently 
increased on a per cell average during ViaCell’s 14-days of ex-vivo expansion of UCB-
derived HSCs and primitive cells.  Telomerase activity is further apparently increased 
after removal of differentiated cells, which are known to be low in telomerase activity.  
Telomere lengths also increased in the cell populations enriched for primitive cells 
including HSCs after removal of differentiated cells.  Differentiated Lin+ cells showed a 
300% decrease in telomerase activity compared to Post-Sep-2 and showed very short 
telomere lengths.  This work also shows that telomerase activity and telomere lengths 
decrease upon cell amplification and differentiation.  Finally, we show that telomerase 
activity and telomere lengths do not correlate with CD34+CD38- content. 
 
 
 
 
 24
MATERIALS AND METHODS 
 
Acquisition of Cord Blood Samples 
    Human umbilical cord blood samples were provided by ViaCell Inc. (Worcester, 
MA).  The cord blood samples were donated to ViaCell from UMass Memorial Hospital. 
For the TRAP assay, at least 105 CD45+ cells were provided at various time points during 
ViaCell’s stem cell amplification process.  Using this assay, cord cell samples from five 
different donors were tested.  For the telomerase length assay (TLA), at least 6 X 106 
CD45+ cells from three pooled donors were required for genomic DNA isolation.  Cells 
were cultured in Stem Span Medium (Stem Cell, Vancouver B.C., Cat #09650) 
supplemented with chemically defined lipid (0.2% final concentration) (Gibco, Cat 
#11905-031) and gentamycin (0.1% final concentration) (Mediatech, Cat #30-005-CR).  
Before being transported to WPI, the cultured cells were left in an aliquot of original 
culture media or PBS on ice.  
 
TRAP (Telomerase Repeat Amplification Protocol) Assay  
This assay (Kim et al., 1994; Wright et al., 1995) was performed as described in 
the specification manual (Intergen) with a few exceptions. 
 
Cell Extract/Lysate Preparation 
Cord blood whole cell extract was prepared using 1X CHAPS lysis buffer (10 
mM Tris-HCl, pH 7.5, 1 mM MgCl2, 1 mM EGTA, 0.1 mM Benzamidine, 5 mM β-
mercaptoethanol, 0.5% CHAPS, 10% Glycerol) supplied with the TRAPeze telomerase 
detection kit (Intergen, #S7700).  Cord blood cell samples containing at least 105 CD45+ 
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cells were microfuged for 15 sec at room temperature to pellet the cells.  The supernatant 
was discarded.  This centrifugation was performed twice to thoroughly remove all the 
media or PBS that the cells were suspended in.  Cell pellets from 105 cells were 
resuspended in 20 µl 1X CHAPS lysis buffer by pipetting up and down.  For 106 cells, 
200 µl of 1X CHAPS lysis buffer was used.  The suspension was incubated on ice for 30 
min.  The lysate was then spun in a microcentrifuge at 10,000 xg for 20 min at 4oC to 
pellet cell debris.  The supernatant was aliquoted and stored at –80oC.  5 µl of supernatant 
of each sample was transferred into a fresh eppendorf tube to determine the protein 
concentration.  
 
Determination of Protein Concentration 
Protein concentrations were determined for whole cell lysates using a Coomassie 
assay (Pierce) and a BSA standard curve.  BSA standard dilutions were prepared at the 
following concentrations: 1.25 µg/ml, 2.50 µg/ml, 5 µg/ml, 10 µg/ml, 20 µg/ml, and 40 
µg/ml.  In the first tube, 500 µl distilled water was added.  In the second tube, 5 µl of cell 
extract was diluted with 495 µl of distilled water.  In the remaining tubes 500 µl of each 
of the BSA standard dilutions were added.  To equalize the temperature, all the tubes 
were incubated at 37oC for 1 min.  0.5 ml of Coomassie protein assay reagent (Pierce) 
was added to each tube.   Samples were mixed, and then the OD was read at 595 nm 
relative to the tube containing only distilled water as “blank”.  
 
TS Primer Kination 
End labeling of the TS primer was performed according to Intergen’s TRAPeze 
Telomerase detection protocol (#S7700).  The TS primer (5’-
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AATCCGTCGAGCAGAGTT-3’) was 5’ end labeled with [γ-32P]-ATP (ICN 
Pharmaceuticals, 3000 Ci / mmol) using T4 polynucleotide kinase (Ambion).  All the 
reagents were thawed and kept on ice.  The following reagents were combined in a 0.5 ml 
eppendorf tube to make a 20 µl reaction: 10 µl of TS primer, 2.5 µl of [γ-32P]-ATP (3,000 
Ci/mmol), 2 µl of 10X kinase buffer, 0.5 µl T4 polynucleotide kinase (10 units/µl) 
(Ambion, #2310) and 5 µl of PCR grade water.  These reagents were then mixed and 
spun briefly in a microcentrifuge.  The reagent mix was incubated for 20 min at 37oC, 
then for 5 min at 85oC to inactivate the kinase.  The kinased samples were stored at  
−20oC in a lead pig.   2 µl of kinase-labelled TS primer were used per TRAP assay 
reaction. 
 
Telomerase Reaction and PCR 
A ‘Master Mix’ was prepared for the PCR amplification according to Intergen’s 
TRAPeze Telomerase detection protocol (#S7700). The master mix was prepared by 
combining the following reagents in a 1.5 ml eppendorf tube. All reagents were thawed 
and kept on ice.  The amount of reagents used for each assay was as follows: 5 µl of 10X 
TRAP reaction buffer (200 mM Tris-HCl, pH 8.3, 15 mM MgCl2, 630 mM KCl, 0.5% 
Tween 20, 10 mM EGTA), 1 µl of 50X dNTP mix (2.5 mM each dATP, dTTP, dGTP, 
dCTP), 2 µl 32P-labeled TS primer, 1 µl TRAP primer mix (RP primer, K1 primer, TSK1 
template), 0.4 µl of Taq polymerase (5 units/µl, Amersham Pharmacia Biotech, #27-
0799-01), and 38.6 µl of PCR grade water.  The tubes were vortexed and spun briefly in a 
microcentrifuge.  For each assay, 48 µl of the ‘Master Mix’ was aliquoted into a 0.5 ml 
eppendorf tube.  One of the following sample cell extracts or controls was added to the 
master mix aliquoted in each tube: 2 µl of CHAPS lysis buffer (primer-dimer/PCR 
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contamination control), 2 µl of heat inactivated extract (negative control), 2 µl of cancer 
cell line positive control, or a volume of cord cell extract containing 1 µg of protein 
(usually 0.5-2 µl).  The tubes were then mixed and spun briefly in a microcentrifuge. The 
tubes were placed in a thermocycler and incubated at 30oC for 30 min to allow ladder 
extension of the TS primer.  A 2-step PCR was then performed at 94oC/30 sec, and 
59oC/30 sec for 27 cycles.  Following PCR, the samples were stored at 4oC, or the PCR 
products were analyzed on a 10% non-denaturing polyacrylamide gel.  
 
TRAP Gel Electrophoresis 
The TRAP reaction products were analyzed on a 0.8 mm 10% non-denaturing 
polyacrylamide gel containing 0.5x TBE.  First, the BRL V-16 glass plates were set up 
using 0.8 mm thick spacers and comb.  A narrow toothed comb was used to analyze more 
samples.  30 ml of gel solution was prepared by mixing 10 ml of 30% polyacrimide / 
bisacrylamide, 1.5 ml of 10X TBE, 0.6 ml of 5% ammonium persulfate (to make 0.1%), 
dH2O to make 30 ml, and 15 µl TEMED to make a 0.8 mm thick, 7 inches long, 10% gel.  
The gel was left to polymerize for 30 min, then the comb and lower spacer were 
removed.  The gel was mounted into the electrophoresis unit, and the upper and lower 
reservoirs were filled with 0.5X TBE buffer.  Before loading the samples, the gel was 
pre-electrophoresed at 287 V for 15 min.  5 µl of 10X loading dye-containing 
bromophenol blue and xylene cyanol (0.05% each) and 10% glycerol was added to each 
PCR reaction tube.  The tubes were then vortexed and spun in a microfuge.  5 µl from 
each of the reaction tubes was loaded per lane. The remaining reaction mixes were stored 
at 4oC.  The gel was then electrophoresed at 287 V for 1 hour and 30 min, until the 
xylene cyanol ran 70-75% of the gel length. 
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Gel Drying and Autoradiography 
After electrophoresis, the radioactive electrode buffer was discarded in the isotope 
sink and the PAGE unit was dismounted.  The gel was separated from the glass plates, 
and the lower right corner of the gel was marked for orientation.  The gel was then 
carefully spread out on 2 layers of 3 MM filter paper and was covered with saran wrap. 
The gel covered with saran wrap was placed in the gel drier and dried for 1 hour at 80°C.  
The telomerase reaction products on the dry gel were then visualized by autoradiography 
using Kodak X-OMAT AR X-ray film. 
 
TRAP Assay Quantitation 
The telomerase products were quantified using a Dupont Benchtop Radioisotope 
Counter.  Radioactive India ink was used to orient the gel with the X-Ray film.  Then the 
portion of the gel corresponding to the P32-labeled telomerase reaction products (i.e. all 
bands ≥ 50 bp) was carefully cut out from the gel, squished into an eppendorf tube, and 
placed in the counter.  The radioactive signal was read as counts per minute (CPM).  
 
Telomere Length Assay  
This assay (Chang and Harley, 1995; Lansdorp et al., 1996) was performed 
essentially as described in the specification manual (Roche) with a few exceptions. 
Acquisition of Cord Blood Samples 
Human umbilical cord blood samples containing at least 6 X 106 CD45+ cells 
were obtained from 2-3 pooled donors at various time points during ViaCell’s stem cell 
amplification process.  For the Telomere Length Assay (TLA), at least 6 X 106 cells were 
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required to obtain a good yield of genomic DNA.  The cultured cells were transported to 
WPI in an aliquot of original culture media or PBS on ice.  
  
Isolation of Genomic DNA 
A genomic DNA isolation procedure based on magnetic bead technology was 
performed at room temperature according to Roche’s DNA isolation protocol (Roche, 
#2032805).  This method utilizes the ability of nucleic acids to adsorb to silica (glass) in 
the presence of a chaotropic salt.  The volume of reagents used for DNA extraction was 
taken from Roche’s chart for 1 X 107 cells.  All the reagents used were supplied in the 
DNA isolation kit for Blood/Bone Marrow/Tissue (Roche, #2032805).  First the media 
containing the cells was split into 4 eppendorf tubes.  Cord blood cells were pelleted by 
low speed centrifugation at 2000-3000 rpm for 2-3 min. The following reagents were 
pipetted into a fresh 15 ml plastic tube to prepare the lysis buffer solution: 2 ml of lysis 
buffer, 2 ml of distilled water.  The contents of the tube were then mixed.  The four ml of 
diluted lysis buffer solution were added to the pelleted cells split into four eppendorf 
tubes (1 ml per pellet) and the tubes were vortexed gently.  The cell solution was mixed 
with 200 µl of proteinase K (50 µl per each of the 4 eppendorf tubes) and vortexed twice 
for 10 seconds.  This treatment helps ensure cell lysis and inactivation of nucleases.  
Then 10 Magnetic Glass Particles (MGP) tablets (approx. 2-3 tablets per eppendorf tube) 
were added to the lysate to immobilize the DNA.  The lysate with the beads was vortexed 
for 10 sec, causing the beads to break into a powdered form to bind DNA more 
efficiently.  The lysate was incubated for 5 min at room temperature with slow 
continuous inverted mixing by hand.  Next, the MGP beads were separated by placing the 
eppendorf tubes in a magnetic particle separator (Roche # 1641794) for 2 minutes, and 
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the supernatant was discarded.  In a separate tube, washing buffer solution containing 
RNase was prepared by mixing 10 µl RNase solution with 5 ml of washing buffer.  The 
separated MGP pellet was suspended in the RNase mixture (1.25 ml for each of the 4 
eppendorf tubes) and incubated for 5 min at 37oC.  This treatment with RNase was done 
to remove minor contaminations of the DNA sample with RNA.  The MGP pellet was 
again separated in a magnetic particle separator and the supernatant was removed. Next, 
the MGP pellet was washed by repeated steps of separation and resuspension.  The MGP 
pellet was washed twice using washing buffer solution without RNase, as follows: the 
separated MGP was suspended by pipetting in 5 ml (1.25 ml for each of the 4 eppendorf 
tubes) of washing buffer, and separated by placing the tube in a magnetic particle 
separator for 2 min. The wash supernatants were completely removed and discarded.  
Finally the DNA was eluted from the MGP pellet in the following manner: the MGP 
containing the DNA was resuspended in 1 ml (0.25 ml per eppendorf tube) of elution 
buffer, and incubated for 5 min at 70oC on a heating block with intermittent vortexing.  
This was followed by microcentrifugation for 4 min at 13000 rpm.  The supernatant 
containing the DNA was then aliquoted and stored at –20oC.  
 
Ethanol Precipitation of Isolated DNA 
In some instances, the DNA isolated using the above procedure was not pure 
enough to be cut by the restriction enzymes used in the TLA.  Hence, I ethanol precipated 
the DNA.  To 400 µl of the DNA solution obtained from the above procedure, 40 µl of 
3.0 M NaOAc, pH 7.0 (one tenth the volume of the DNA sample) was added.  1 µl of 
glycogen (10 mg/ ml, 10 µg) was added to act as carrier.  This solution was mixed well 
before adding 1.1 ml of ethanol (2.5 times the volume of the DNA sample).  This mixture 
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was incubated overnight at –20o C.  It was then microfuged for 15 minutes at room 
temperature.  The supernatant was carefully decanted leaving the pellet undisturbed.  The 
pellet was then washed by adding 0.5 ml of 100 % ethanol and inverted mixing.  It was 
then immediately microfuged for 15 minutes.  The supernatant was very carefully 
removed without dislodging the loose pellet.   The DNA pellet was then air dried and 
dissolved in 1X TE buffer (to give about 1 µg/ µl concentration of DNA, usually 30 µl), 
and heated for five minutes at 50o C to aid dissolution.  
 
Digestion of Genomic DNA 
The digestion of genomic DNA isolated from cord blood cells was performed 
according to Roche’s TeloTAGGG Telomere Length Assay protocol (#2209136).  Per 
sample, 1 µg of extracted genomic DNA was diluted with nuclease free water (supplied 
in the TeloTAGGG Kit) to a final volume of 16 µl.  Handling of all solutions and 
pipeting was done on ice.  The following reagents were added to the 16 µl to make a 20 
µl reaction: 2 µl of 10X digestion buffer, 1 µl of Hinf 1 (40 U/µl), and 1 µl of Rsa 1 (40 
U/µl).  As controls, 1 µg of high molecular weight control DNA (high molecular weight 
telomeres, 100 ng/µl), and low molecular weight control DNA (low molecular weight 
telomeres, 100 ng/µl) or cord sample) in 16 µl volume were also tested.  The reaction 
mixture was then incubated for 6 hours at 37o C.   Again 1 µl of Hinf 1 (40 U/µl) and 1 µl 
of Rsa 1 (40 U/µl) were added to each of the reaction mixtures and left overnight at 37o 
C.   This was an exception to Roche’s protocol.   Before loading onto the gel, 5 µl of 5X 
loading buffer was added to each 20 µl reaction to make a final volume of 25 µl. 
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Genomic DNA Electrophoresis 
Digested genomic DNA was separated by agarose gel electrophoresis. A 0.8% 
horizontal agarose gel was prepared as follows: 0.8 g of highly pure nucleic acid grade 
agarose (International Biotechnologies Inc.) was added to 100 ml of 1X TAE buffer in an 
Erlenmeyer flask.  The solution was heated in a microwave oven for 2-3 min until the 
agarose was fully dissolved.  The hot agarose solution was then poured into an 8 cm x 10 
cm electrophoresis tray, and left to solidify at room temperature for 45 min.  Once the gel 
solidified, the gel comb was removed and the electrophoresis unit was filled with 1X 
TAE running buffer.  The digoxygenin DIG molecular weight marker mix was prepared 
just before loading the samples onto the gel by mixing in a 0.5 ml eppendorf tube: 4 µl of 
DIG molecular weight marker, 12 µl of nuclease free water, and 4 µl of 5X loading 
buffer.  This 20 µl marker sample was microfuged briefly and incubated at 65oC for 10 
min.  25 µl of each cord sample were loaded per lane and 10 µl of the DIG labeled 
molecular weight marker were loaded on each side of the gel.  The gel was 
electrophoresed at 22 V for 5 hours until the Bromophenol blue tracking dye had traveled 
approximately ¾ the length of the gel. 
 
Southern Blotting 
Southern transfer of the digested genomic DNA was performed by high salt 
capillary transfer to nitrocellulose membrane using a 20X SSC (Sodium Saline Citrate, 3 
M NaCl, 0.3 M Sodium Citrate, pH 7.0) transfer buffer.  After electrophoresis, a small 
piece from the lower right corner of the gel was cut for orientation purposes.  All the gel-
washing steps were performed with gentle agitation on a gyrotory shaker at 25°C in a 
tupperware dish.  The gel was first submerged in for 5-10 min in HCl solution (0.25 M 
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HCl) until the BPB went yellow. This step was done to fragment the DNA, to facilitate 
the transfer.  The gel was rinsed 2 times with distilled water, then was denatured to single 
strands by submerging 2 times for 15 min in Denaturation solution (0.5 M NaOH, 1.5 M 
NaCl). This was followed by rinsing the gel two times with distilled water, and 
neutralization by submerging it two times for 15 min in Neutralization solution (0.5 M 
Tris-HCl pH 7.5, 3 M NaCl).   All washes were decanted to waste.  
Nitrocellulose membrane (BA-45, 0.45 µm pore size) and two 3MM filter papers 
cut to the size of the gel were pre-soaked in 2X SSC buffer for 30 min before blotting the 
gel to the membrane.  This was done to decrease the chance of bubble formation and to 
facilitate the transfer of the DNA.  The digested DNA from the gel was blotted to the 
nitrocellulose membrane by capillary transfer at 25°C using 20X SSC as a transfer buffer.  
The southern blot transfer was performed as follows: a tupperware dish was used as the 
transfer unit, and a piece of dry 3MM filter paper served as a wick in the transfer unit.  
The tupperware dish was then filled with 20X SSC buffer and the ends of the wick were 
submerged in the buffer.  Extra buffer was poured over the wick, and all the air bubbles 
were removed by smoothing out the wick using a gloved hand.  One of the pre-moistened 
3MM filter paper squares was then placed on top of the wick.  The gel was placed on the 
3MM sheet and all air bubbles were removed.  The pre-moistened nitrocellulose 
membrane was then placed over the gel, and its corner corresponding to the gel was also 
cut, and all air bubbles were removed.  Another pre-moistened 3MM filter paper was then 
layered over the membrane.  Next, a sheet of saran wrap was placed over the whole unit 
and the center of the saran wrap corresponding to the size of the gel was cut out.  The 
saran wrap was then overlayered with a piece of dry 3MM paper, which in turn was 
overlayered with several layers of dry paper towels to make a stack about 10 cm thick.  
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The paper towels were placed so that they did not directly touch the SSC buffer in the 
tupperware dish, as this would short-circuit the flow of buffer through the gel.  The paper 
towels were covered with a glass plate, and a big book was placed on top of the plate as a 
weight.  The blot was allowed to sit overnight for maximum sensitivity and 
reproducibility of transfer. After blotting, the membrane was washed in 2X SSC solution.  
The membrane was then placed between 2 sheets of dry 3MM filter paper cut to the size 
of the membrane, and baked at 120oC in a glassware drying oven for 2 hours.  If not used 
immediately for hybridization and chemiluminescence detection, the membrane was 
wrapped in a foil and stored at 4oC. 
 
DNA Hybridization 
The hybridization and chemiluminescence detection steps were performed  
according to Roche’s TeloTAGGG Telomere Length Assay protocol (Roche, #2209136). 
The hybridization and wash temperatures were precisely controlled for maximum 
sensitivity and reproducibility of results.  The hybridization was performed as follows: 
the DIG hybridization solution was pre-warmed to 42oC.  For pre-hybridization, the 
membrane was submerged in 10 ml of pre-warmed DIG hybridization solution in a 
hybridization bag, and incubated for 30-60 min at 42oC on a gyrotory shaker. 
Hybridization solution was prepared by adding 1 µl of telomere probe (DIG labeled 
telomere specific hybridization probe, Roche, #2209136) to 5 ml pre-warmed hyb-
solution, and mixed.  After pre-hyb incubation of membrane, the pre-hyb solution was 
discarded and the 5 ml Hybridization solution containing the telomere probe was 
immediately added.  The membrane was incubated in a hybridization bag for 3 hours at 
42oC on a gyrotory shaker. After hybridization, the Hybridization solution was discarded, 
and the membrane was washed 2 times with 100 ml stringent wash buffer-I (2X SSC, 0.1 
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SDS) for 5 min at 25oC with gentle agitation.  The membrane was then washed 2 times 
with pre-warmed stringent wash buffer-II (0.2X SSC, 0.1 SDS) at 50oC with gentle 
agitation. These washes were followed by rinsing the membrane in washing buffer-1X 
(supplied with the Roche kit # 2209136) for 1-5 min at 25oC on a gyrotory shaker.   
 
DIG Antibody Binding 
The membrane was then incubated in freshly prepared Blocking solution (by 
mixing 15 ml of 10X Roche Blocking solution with 135 ml maleic acid buffer) for 30 
min on a gyrotory shaker at 25oC.  The antibody solution was prepared as follows: The 
vial containing the Anti-DIG –AP antibody (0.75 U/µl, Fab fragments of a polyclonal 
antibody from sheep, conjugated to alkaline phosphatase (AP), Roche, #2209136) was 
microfuged at 13,000 rpm for 5 min. This was done to remove particulates to reduce 
background by aggregated antibody.  The antibody was then diluted 1:10,000 with fresh 
blocking solution by adding 5 µl antibody to 50 ml blocking solution.  The membrane 
was incubated in this solution for 30 min at 25oC on a gyrotory shaker.  This was 
followed by washing the membrane 2 times with 100 ml washing buffer-1X at 25oC on a 
gyrotory.  
 
TLA Chemiluminescence Detection 
The membrane was then incubated in 100 ml detection buffer-1X for 2-5 min at 
25oC on a gyrotory.  The membrane with the DNA side up was then placed on a dry 
3MM filter paper, placed on top of a clear plastic sheet, so that the membrane did not dry 
completely.  3 ml of substrate solution (containing CDP-Star, a highly sensitive 
chemiluminescence substrate) was applied immediately.  A second plastic sheet was 
immediately used to cover the membrane so that the substrate solution spread evenly.  All 
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bubbles over the membrane were removed, and the membrane was incubated for 5 min at 
25oC.  Excess substrate solution was squeezed out from the plastic sheets, and the 
membrane was exposed to Kodak XAR-5 X-ray film for 1 hour at 25oC.   Luminescence 
continued for 24 hours allowing multiple exposures.  The signal intensity increased 
during the first few hours, so weak initial exposures were strengthened by waiting 1-2 
hrs. 
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RESULTS 
 
 
The purpose of this project was to test two hypotheses that telomerase activity and 
telomere lengths 1) appear to increase upon removal of differentiated Lin+ cells, and 2) 
decrease upon differentiation and proliferation of hematopoietic cells.  We investigated 
telomerase activity and telomere lengths in human cord blood hematopoietic cell 
populations obtained from Viacell Inc. at various intervals of a two-week ex vivo stem 
cell amplification process.  We also quantified the data and estimated the inter-cord and 
intra-cord variability by analysis of variance (ANOVA). 
 
Time Course of ViaCell’s HSC Amplification Protocol 
 
The main goal of this project was to analyze telomerase activity and telomere 
lengths throughout ViaCell’s entire selection/ amplification protocol.  Table 3 lists 
various time points of ViaCell’s two-week ex vivo stem cell amplification process, with 
typical cell numbers and the typical CD34+CD38- content of each time point. The time 
course corresponds to ViaCell’s 14-day long amplification process.  During this process, 
fresh whole cord blood mononuclear cells, which are un-amplified and termed ‘Pre-
Freeze’ or Day-0, are first frozen and thawed. After thawing (‘Post-Thaw’ and ‘Pre-Sep-
1’), these cells undergo the first of two rounds of ‘Negative Selection’ separation to 
remove differentiated cells.  The cell population is termed ‘Pre-Sep-1’ before passage 
over the column, and ‘Post-Sep-1 after the first separation.  After the first separation, the 
cells are grown for a week in medium supplemented with a combination of cytokines 
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known to stimulate HSC growth.  These cells then undergo a second round of separation.  
The cell populations are called ‘Pre-Sep-2’ and ‘Post-Sep-2, before and after the second 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
separation step, respectively.  These two stages correspond to ‘Day-7’ and ‘Day-7.5’ 
respectively.  After the second separation, the cells are grown in culture for an additional 
week and are called ‘Cell Product’ or ‘day 14’. These cells are usually frozen for storage. 
Upon thawing the cells are termed ‘thawed day 14’ (not shown on the time course). In 
one experiment, after the second separation, the cells were grown for a week in culture 
supplemented by a combination of cytokines including all-trans-retinoic acid (ATRA) 
known to induce differentiation of HSCs and primitive progenitor cells.  This cell fraction 
is termed as ‘Pre-Sep-3’.  Note that the Post-Sep-2 sample contains the highest 
10.53 ~3.0 x 107Post Culture 
With proliferation-
inducing cytokines 
Day 14 
N/A N/A Post Culture 
With differentiation-
inducing Cytokines  
Day 14 
(Pre-Sep-3) 
 
33.20 ~6.2 x 106 Post-Sep-2 Day 7.5 
31.25 ~2.1 x 107 Pre-Sep-2 Day 7 
3.20 ~2.7 x 106 Post-Sep-1 Day 0.5 
0.17 ~5.2 x 107 Post-Freeze 
Pre-Sep-1
Day 0 
0.26 ~6.5 x 108 Pre-freeze Day 0 
Fresh Cord 
Percentage of 
CD34+CD38- 
Typical Cell 
Number 
Cell Sample Fraction Time 
Table 3.  Steps During ViaCell’s HSC Amplification Protocol.
FACS data for cord-3 is shown representing typical CD34+CD38- content for each time point. 
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percentage of CD34+/CD38- cells, representing approximately 128-fold enrichment of 
these cells over fresh cord. 
 
An Overview of Telomerase Activity throughout ViaCell’s Process 
 
A TRAP (Telomerase Repeat Amplification Protocol) assay was used to measure 
telomerase activity throughout ViaCell’s entire selection/ amplification protocol.  For the 
time course experiments, at least 105 CD45+ (marker for hematopoietic cells) cells were 
provided at various time-points in ViaCell’s amplification process.  Because the TRAP 
assay is so sensitive, samples could be obtained from individual cords without pooling.  
Whole cell lysates were prepared from each sample.  1 µg of cord whole cell lysate 
protein load, previously determined to be the optimum protein load for the assay for 
cords-1 and 2 (Murthy, 2002) was used for the time course experiments.  A single 
‘Master Mix’ for the PCR amplification was used to assay all the samples from one cord, 
which proved to be critical for obtaining an even amplification of the internal 36 bp PCR 
control.  The 36 bp internal PCR control was observed in all lanes, which indicates no 
cord sample contained an unusual amount of Taq Polymerase inhibitor.   
Figure 7 shows duplicate determinations for cord-3.  As expected, high 
telomerase activity was detected in the cancer cell extract positive control (lane M).  
Telomerase activity was undetected early in ViaCell’s process, in ‘pre-freeze’ (Day-0), 
‘Post thaw’ and ‘Pre-Sep-1’ time points (lanes 1-3) that theoretically represent quiescent 
cells. Telomerase activity was low but detectable in ‘Post-Sep-1’ (lane 4), was high in  
‘Pre- Sep-2’ (lane 5), and peaked at ‘Post-Sep-2’ (lane 6).  Telomerase activity at ‘Post-
Sep-2’ (Day-7) was higher than that of the cancer cell extract positive control (lane M).  
At ‘Day-14’, however, a decrease in telomerase activity was observed.  The activity 
increased following freeze/thaw of the ‘Day-14’ fraction.  These results indicate that 
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telomerase activity is low or undetectable when the cells are quiescent (‘pre-freeze’ (Day 
0), ‘Post thaw’ and ‘Pre-Sep-1’) and increase when the cells are stimulated by cytokines 
to proliferate (‘Post-Sep-1’, ‘Pre- Sep-2’, ‘Post-Sep-2’).  The highest telomerase activity 
 
         
                   
  
 
A. Cord 3, # 1 
B. Cord 3, # 2 
Figure 7.  Telomerase Activity is Low in Quiescent Cells and Increases in Proliferating Cell 
Populations.  TRAP assay on cord 3, #1 (top), and # 2 (bottom) 
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was seen in the ‘Post-Sep-2’ cell fraction, which superficially appears to correlate with 
cell population containing the highest percent CD34+CD38- cells (which are known to be 
high in telomerase activity).  A dip in telomerase activity at ‘Day-14’ is expected in 
rapidly proliferating cell population, which is also known to contain differentiated cells. 
Surprisingly, there was resurgence in telomerase activity in ‘thawed-day 14’ cells 
which only differ from the ‘day 14’ cells by a single round of freeze/thaw.  We speculate 
this may result from a higher survivability of cells during the freeze/thaw that contain 
telomerase.  However, a more detailed investigation is required to prove this. 
 Figure 7 lower panel represents trial # 2 for Cord 3.  This second trial showed the 
same trends in telomerase activity as trial 1.  Figure 8 shows the quantitation data for 
cord 3 determined by counting the 32P cut from the dried gel that corresponds directly 
with the telomerase ladder rungs from the x-ray films.   The Post-Sep-2 sample (130%) 
showed a 120% increase in activity over fresh cord (10%) (p = 0.0001, Tukey-ANOVA 
test). 
Figure 8.  Quantitation of Telomerase Activity in Cord-3.  The Y-axis shows values as percent 
activity relative to the cancer cell positive control.  Histobars represent the mean telomerase 
activity of the two trials for cord 3. The Post-Sep-2 sample (130%) showed a 120% increase in 
activity over fresh cord (10%) (p = 0.0001, Tukey-ANOVA test) (*). 
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Telomerase Activity Apparently Increases in Post-Sep Cells Relative to Pre-Sep and 
Decreases upon Differentiation and Proliferation 
  To test the hypotheses that telomerase activity will appear to increase 
upon the removal of differentiated cells, and decrease upon differentiation of 
hematopoietic cells specific fractions from cord 4 were analyzed.  After post-sep-2, we 
let the selected primitive cells mature and differentiate for a week (Pre-Sep-3) under the 
influence of a combination of differentiation-inducing cytokines (ATRA).  Table 4 shows 
FACS data for cord-4.  In this particular cord (unlike cord-3) note the strong increase in  
CD34+CD38- cells Post-Sep-1 relative to Pre-Sep-1, but only a slight percent increase in 
CD34+CD38- cells Pre-Sep-2 vs Post-Sep-2.  Also note the substantial decrease in 
percent CD34+CD38- cells for the Pre-Sep-3 sample.   
 
 
 
 
 
 
Figure 9 shows the TRAP data for cord-4, and figure 10 its quantitation.  The 
TRAP analysis revealed that both post-column separation cell populations (Post-Sep-1 
and Post-Sep-2; lane 2 and lane 4 respectively) showed apparent increases in telomerase 
activity compared to their corresponding pre-column separation cell populations (Pre-
Sep-1 and Pre-Sep-2 respectively; lane 1 and lane 3).  For this cord, the increase was 
especially prevalent for the Post-Sep-1 sample that showed the greatest increase in 
CD34+CD38- cells relative to before the column.  Thus the removal of differentiated cells 
can have a substantial effect on the apparent telomerase activity of the remaining cells. 
Table 4.  Percent CD34+CD38- Content for Cord-4.
22.30 
Pre-Sep-3
(Day-14) 
79.78 75.42 85.09 0.81 CD34+CD38- 
(%) 
Post-Sep-2 
(Day-7.5) 
Pre-Sep-2 
(Day-7) 
Post-Sep-1
(Day-0.5) 
Pre-Sep-1 Cord- 
Sample 
(Cord-4) 
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The Pre-Sep-3 cell fraction showed low to undetectable telomerase activity.  This 
indicates that telomerase activity apparently decreases upon differentiation and 
proliferation of ViaCell’s hematopoietic cells.  Post-Sep-1 and Post-Sep-2 showed about 
 
                
 
 
Figure 9.  Telomerase Activity Apparently Increases in Post-Sep Relative to Pre-Sep Cells and 
Decreases Upon Cell   Differentiation and Proliferation.  TRAP assay on Cord 4, # 1. 
Figure 10.  Quantitation of Telomerase Activity in Cord-4, # 1.  The Y-axis shows values as 
percent activity relative to cancer cell positive control.  
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707% and 22% increase in telomerase activity over Pre-Sep-1 and Pre-Sep-2 cell 
populations respectively (p = 0.0001, Tukey-ANOVA test).  Pre-Sep-3 showed about 702 
% decrease in telomerase activty compared to Post-Sep-2 (p = 0.0001, Tukey-ANOVA 
test).    
 
 The TRAP Assay is Highly Reproducible with Low Intra-Cord Variability 
 
In order to determine the intra-cord variability in the TRAP assays, we analyzed 
the telomerase activity in cord-4 five more times (Figure 11).  All five TRAP assays 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11.  Several TRAP Assays on Cord 4.  # 2 (top left), # 3 (top right), # 4 (center), # 5 (bottom 
left), # 6 (bottom right). 
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showed the same trend in telomerase activity as in the previous figure.  All six 
determinations for cord-4 are quantitated in figure 12.  The low standard deviations 
indicate that the TRAP assay is highly reproducible with low intra-cord variability.  
Moreover, the quantitation data is in agreement with the trends in telomerase activity for 
cord-3 as seen in figures 10 and 11, although the sep-1 difference was smaller, and the 
sep-2 difference was larger.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12.  The TRAP Assay is Highly Reproducible with Low Intra-Cord Variability.
Telomerase activity was measured relative to a cancer cell extract positive control set at 100%. 
Histobars represent the mean telomerase activity for six TRAP assays on cord 4.  Error bars represent
the standard deviations from the mean. Statistical analysis was performed on logarithm-transformed 
data using the Tukey-ANOVA test (logarithms are more normally distributed than ratios).  Post-Sep 
samples were found to be significantly different than Pre-Sep samples (**P < 0.0001).  Telomerase 
activity sharply declined in Pre-Sep-3 compared to Post-Sep-2 (*P < 0.0001). 
Sample # 1 # 2 # 3 # 4 # 5 # 6 Mean Std Dev
Positive control 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Pre-Sep-1 9.9 8.9 9.3 9.6 7.0 6.1 8.5 1.5
Post- Sep 1 79.0 75.6 78.7 79.5 66.7 77.6 76.2 4.9
Pre- Sep 2 91.4 87.8 84.0 88.0 82.5 89.8 87.2 3.4
Post- Sep 2 109.9 108.9 114.7 116.9 103.5 114.3 111.3 4.9
Pre- Sep 3 13.6 12.2 16.0 16.9 15.8 14.3 14.8 1.7
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Inter-Cord Variability 
Serum cytokine levels are known to vary among cord donors, which could affect 
hematopoiesis.  Inter-cord variability was investigated for four cords (the first two cords 
were analyzed by Vidya Murthy and the next two by myself) as shown in figure 13.  
Unlike intra-cord variability, higher inter-cord variability in telomerase activity was 
observed with standard deviations from the mean activity ranging from 9% to 33%.  
Although the stand deviations are larger than for single cords, the data still support both 
the hypotheses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13.  Inter-Cord Variability.   Telomerase activity was measured relative to a cancer cell 
extract positive control set at 100%.  Histobars represent the mean telomerase activity for four different 
cords, Cords 1-4.  Error bars represent the standard deviations from the mean.    Statistical analysis was 
performed on logarithm-transformed data.  The Post-Thaw sample could not be statistically analyzed 
because only two of these cell fractions were available.   Post-Sep-1 and Post-Sep-2 showed an 87% 
and 60% increase in activity over Pre-Sep-1 and Pre-Sep-2 cells respectively (** p = 0.001).  Day-14 
cells showed a 52% decrease in telomerase activity relative to Post-Sep-2 (* p = 0.001). 
         Vidya's Data                     Manish's Data
Sample N1 N2 N3 N4 Mean Std Dev
Marker 100 100 100 100 100
Pre-Freeze 22 5 18 ND 15.0 8.9
Post-Thaw 22 ND 24 ND 23.0 N/A
Pre-Sep-1 28 ND 30 10 22.7 11.0
Post-Sep-1 35 18 38 78 42.3 25.4
Pre-Sep-2 60 50 82 85 69.3 17.0
Post-Sep-2 122 85 130 110 111.8 19.6
Day-14 70 30 62 ND 54.0 21.2
Thawed Day-14 100 42 98 ND 80.0 32.9
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Removal of Telomerase-Low Differentiated (Lin+) Cells Apparently Increases 
Telomerase Activity in Post-Sep Cells 
 From our TRAP data, we hypothesized that removal of telomerase-low 
differentiated (Lin+) cells is responsible for the apparent increase in telomerase activity in 
Post-Sep cells.  To test this hypothesis, we analyzed telomerase activity in Lin+ cells 
during a sep-1 separation.  Table 5 shows the percent CD34+CD38- cells in Pre- and Post-
Sep-1 fractions for cords 5 - 7.  The FACS data for Lin+ cells was unavailable for these 
cords.   
 
 
 
 
 
 
Figure 14 shows the TRAP data for the Sep-1 samples of cords 5- 7. 
 
 
 
 
 
 
 
 
 
 
Table 5.  Percent CD34+CD38- Content of the Pre- and Post-Sep-1 Fractions of Cords 5-7. 
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Figure 14.  Lin+ Cells are Low in Telomerase Activity.  TRAP Assay on Cords 5- 7, # 1 and  # 2 
(left). Lane 1 shows the cancer cell extract positive control, lane 2 shows Pre-Sep-1, lane 3 shows Post-
Sep-1, and Lane 4 shows Lin+.  Quantitation data (right) represents the mean of # 1 and # 2.  As stated 
earlier, telomerase activity was measured relative to the positive control. 
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The statistical summary of the sep-1 fractions for cords 5- 7 is shown in figure 15. 
The Post-Sep-1cell fraction showed 2.98-fold increase in telomerase activity over Pre-
Sep-1 (* P < 0.0001).  Supporting our hypothesis Lin+ cells were observed to be 3.12-fold 
less in telomerase activity compared to Post-Sep-1 (* P < 0.0001).  Lin+ cells were 
removed from the column by pushing about 50 ml 1% BSA/ Saline through the column 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
at a very high flow rate.  Cells were then collected by centrifugation.  It is interesting to 
note that Lin+ cells showed some telomerase activity.  This could be attributed to the 
presence of some cycling mature progenitors present in the Lin+ cell population.   
Figure 15.   Statistical Summary of Cords - 5, 6, and 7.   Telomerase activity was measured relative 
to the  cancer cell extract positive control set at 100%.  Histobars represent the mean telomerase activity 
of # 1 and # 2 for each of the three cords (i.e., two TRAP assays per cord).  Error bars represent the 
standard deviations from the mean.  Statistical analysis was performed on logarithm-transformed data 
using the Tukey-ANOVA test (logarithms are more normally distributed than ratios).  ** p = 0.0001 
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Telomere Length Assay 
 The second goal of this thesis was to test the hypothesis that the telomere lengths 
will appear to increase upon the removal of differentiated cells, and decrease upon 
differentiation and proliferation of hematopoietic cells.  We investigated telomere lengths 
throughout ViaCell’s entire selection/ amplification protocol.  Since there is no reliable 
method of directly measuring the complex assortment of telomere lengths in human cells, 
we and others have assayed mean telomeric restriction fragment (TRF) lengths to detect 
changes in the length of the terminal TTAGGG repeats (Harley et al., 1990; Hastie et al., 
1990; Lindsey et al., 1991).  The mean TRF lengths in human cord blood hematopoietic 
cells were measured using a telomere length assay (TLA) (Harley et al., 1990).   
The length of telomeres is remarkably variable because of the variability in the 
number of TTAGGG repeats (de Lenge et al., 1990).  Telomere lengths show wide inter-
individual variation, and they also vary among cells in the same tissue and among 
chromosomes in the same cell (Blackburn et al., 2000).  Therefore, analyzing a 
population of cells provides the average telomere length of all the telomeres in the 
sample, indicated by a smear whose average size is compared to a molecular weight 
marker.  TRFs comprise not only the variable terminal telomeres but also a brief sub-
telomeric region.  In addition to a molecular weight marker, two positive control DNAs 
were analyzed: Control-DNA-low (mean TRF = 3.7 Kb, obtained from a late-passage 
fibroblast cell line) and Control-DNA-high (mean TRF = 9.5 Kb, obtained from a cancer 
cell line) supplied with the TeloTAGGG kit.  
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Telomere Lengths Decrease upon Expansion and Proliferation of Hematopoietic 
Cells 
To determine the telomere lengths of ViaCell’s hematopoietic cells before and 
after their selection/ amplification protocol, we analyzed the Day-0 and Day-14 cell 
populations by TLA (figure 16).  The Day-14 cell fraction (selected and amplified, ave. 
10.53% CD34+CD38-) (see table 6) was observed to have slightly shorter telomere 
lengths (avg. 9 Kb) compared to the Day-0 cell fraction (fresh cord blood cells) (avg. 10 
Kb) (0.26% CD34+CD38-).  However, as expected of human cord-blood hematopoietic 
cell populations, the telomere lengths of both ViaCell’s fractions were comparable to the 
high DNA control.  Combining the TRAP and TLA data, despite the presence of 
significant telomerase activity in the Day-14 sample, I observed some proliferation-
associated telomeric DNA loss. Therefore, the telomerase activity in that population may 
not be sufficient to completely prevent telomere shortening.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16.  Telomere Lengths Decrease Upon Cell Proliferation and Differentiation.  A. # 1, and 
B. # 2 of the TLA assay on Day-0 and Day-14 cell populations. Lane 1 shows a molecular weight 
marker, lane 2 shows control DNA- low, lane 3 shows control DNA-high, lane 4 shows Day 0 
telomeric DNA and lane 5 shows Day 14 telomeric DNA.
Kb 
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1 52 3 4 
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Telomere Lengths Appear to Increase in Post-Sep Cell Populations 
To determine the effect of the removal of differentiated cells (Lin+) on telomere 
lengths, we analyzed telomere lengths of the Post-Sep cell populations.  In general, as 
expected in cell populations enriched with primitive cells and HSCs, we observed long 
telomeres in Post-Sep-1 and Post-Sep-2 cell fractions, averaging 12 Kb and 14 Kb 
respectively, and 41.58% and 43.57% CD34+CD38- cells (Figure 17).  In another 
experiment, we again found average telomere lengths of Post-Sep-2 to be 14 Kb (data not 
shown) and Post-Sep-1 to be 12 Kb (figure 18) compared to 10 Kb for Pre-Sep-1.   This 
data supports the hypothesis that the removal of differentiated cells will appear to 
increase telomere lengths in the remaining population. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17.  Telomere Lengths Appear to Increase in Post-Sep Cell Populations.  TLA assay on 
Post-Sep-1 and Post-Sep-2 cell populations. Lane 1 shows a molecular weight marker, lane 2 shows 
control DNA- low, lane 3 shows control DNA-high, lane 4 shows Post-Sep-1 telomeric DNA and 
lane 5 shows Post-Sep-2 telomeric DNA.
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Lin+ Cells Have Shorter Telomeres Than Post-Sep-1 Populations  
To determine if the differentiated Lin+ cells removed by column-separation really 
have shorter telomeres than a corresponding Post-Sep population, we analyzed average 
telomere lengths in these cell populations (Figure 18).  Post-Sep-1 cells (63.16% 
CD34+CD38- cells) (avg. 12 Kb) exhibited longer telomeres compared to Pre-Sep-1 cells 
(1.29% CD34+CD38- cells)  (avg. 10 Kb). As expected of differentiated cell populations, 
we observed relatively small telomere lengths in Lin+ cells (7.6 Kb).  Thus, this data 
indicates that the apparent increase in telomere lengths of Post-Sep samples likely results 
from the removal of mature and differentiated cells with shorter telomere lengths. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18.  Lin+ Hematopoietic Cells Have Shorter Telomeres.  TLA assay on Post-Sep-1, Pre-
Sep-1, and Lin+ cell populations. Lanes 1 and 7 show a molecular weight marker, lane 2 shows 
control DNA- low, lane 3 shows control DNA-high, lane 4 shows Post-Sep-1 telomeric DNA, lane 5 
shows Pre-Sep-1 telomeric DNA, lane 6 shows Lin+ telomeric DNA from the sep-1 column. 
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  Subsequent analyses were attempted using New England Biolab’s restriction enzymes 
for genomic DNA digestion (including their digestion buffer instead of Roche’s) (the 
latter was depleted quickly); however, the DNA was not effectively digested using these 
enzymes (data not shown).  The TLA data is summarized in table 6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        Average telomere lengths of two TLA trials on each time point are shown. 
 
 
 
Telomerase Activity and Telomere Lengths Do Not Always Correlate with 
CD34+CD38- Content 
 To determine whether telomerase activity and telomere lengths correlate with the 
percent CD34+CD38- cells in a population we compared a summary of cords 1- 7 TRAP 
and TLA data with FACS analysis data (Table 7).  Upon initial observation, they appear 
to correlate.  For example, for cords 1- 7, the fraction containing the highest telomerase 
activity (Post-Sep-2) also contains the highest percent CD34+CD38- cells.  And the 
fraction containing the lowest telomerase activity (Day-0 Pre-Freeze) also contains the 
lowest percent CD34+CD38- cells.  Upon closer observation, however, we observed that 
Table 6.  Summary Table of Telomere Lengths and CD34+CD38- Content at Various Time Points 
in ViaCell’s Amplification Process.
N/A 
10.53 
43.57 
63.16 
1.29 
0.26 
Percent 
CD34+CD38- 
9 Day 14 
10 Pre-Sep-1 
7.5 Lin + 
14   Post- Sep-2 
12 Post-Sep-1 
10 Day 0 
Avg. Telomere  
Length (Kb) 
Time- point in ViaCell’s 
Amplification 
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telomerase activity and average telomere lengths did not always correlate with 
CD34+CD38- content.  We analyzed individual cord data (cords 1- 4) specifically for 
Post-Sep-2 cell fractions that are relatively enriched with CD34+CD38- cells (Table 8).   
Although cord-4 contained the highest percentage of 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         
 
 
           
                 FACS data and telomerase activity for cords 1-4 are shown for the Post-Sep-2 fractions.  
N/A 
7.8 
39.0
36.6
24.3
0.7
0.2 
Percentage of 
CD34+CD38- 
Cells 
14.8 
54 
111.8
69.3
42.3
29
13.8
Relative Telomerase 
Activity 
(% relative to a 
positive control) 
7.5 
9 
14
N/A
12
10
10
Average 
Telomere 
Length 
(Kb) 
Post Culture 
With proliferation-
inducing cytokines 
Day 14 
Post Culture 
With differentiation-
inducing cytokines 
Day 14 
(Pre-Sep-3) 
 
Post-Sep 2 Day 7.5 
Pre-Sep 2 Day 7 
Post-Sep 1 Day 0.5 
Pre-Sep 1 Day 0 
Pre-freeze Day 0 
Cell Sample 
Fraction 
Time 
Mean   CD34+CD38- content, telomerase activity and TLAs for cords 1-7 are shown. Average telomere 
lengths of all the cell fractions is represented, except Pre-Sep-2.  N/A = not available. 
Cord- 4 
Cord- 3 
Cord- 2 
Cord- 1 
Cord # 
1.4 110 79.78 
4.0 133 33.2 
4.2 84 19.91 
5.3 123 23.09 
Ratio 
Activity/ % CD34+CD38-
Relative 
Telomerase Activity
(% relative to a 
positive control) 
Percentage 
of  
CD34+CD38-
Cells 
Post-Sep-2 
Table 8.  Telomerase Activity Does Not Correlate with CD34+CD38- Content. 
Table 7.  Summary Table of Cords 1- 7: Average of FACS Data with TRAP and TLA Results. 
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CD34+CD38- cells (79.78%) it exhibited lower telomerase activity than cord-1 and cord-
3.  Thus, our results indicate that telomerase activity does not always directly correlate 
with CD34+CD38- content, implying that this activity also resides in other kinds of cells. 
 In summary, our data indicate that the removal of telomerase-low telomere-short 
differentiated (Lin+) cells appears to increase the telomerase activity and telomere lengths 
in the remaining cell population.  Moreover, our data also suggests that telomerase 
activity and telomere lengths decrease upon hematopoietic cell differentiation and 
proliferation.  Lastly, we show that telomerase activity and average telomere length do 
not directly correlate with CD34+CD38- content. 
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DISCUSSION 
 
 
 
Viacell Inc. (Worcester, MA) expands and enriches its populations of cells 
containing HSCs by removing only those Lin+ cells known not to contain HSCs.  This is 
accomplished on two separation columns (post-sep-1, and post-sep-2) (separated by 7 
days of cell growth) that contain a variety of antibodies to known differentiation surface 
markers.  Although this process strongly enriches functional HCSs, these primitive cell 
populations remain biochemically uncharacterized.  Because telomerase activity and 
telomere lengths are known to correlate with the long term proliferation and 
reconstitution potential of hematopoietic cells, it is of utmost importance to Viacell to 
analyze these parameters in their hematopoietic cell fractions slated for transplant into 
patients.   
We quantified the telomerase activity in all the cord blood cell fractions using a 
radioisotope-count based method.  Several attempts have been made by other labs at 
quantifying telomerase activity, ranging from subjective ratings of assay signal 
intensities, to computerized densitometric ladder analyses that control for background 
noise and assay inhibitors.  Quantitative results are probably most meaningfully 
expressed on a per cell basis, but such extremely sensitive assays are often difficult or 
impossible to do.  Therefore our results were presented on a per protein basis.  Even on a 
per cell basis however, the results would not be informative unless one also knows the 
surface marker or functional phenotype of the cell being analyzed.  For example, tumor 
metastases often have higher levels of telomerase activity than those found in the original 
tumor.  The primary tumor is often much more heterogeneous, including normal 
epithelial and stromal cells, as well as varying amounts of extracellular matrix and 
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connective tissue, all of which may act to decrease the proportion of cancer cells in the 
sample (Kim et al., 1994).  The cloning of the genes for the RNA component (Feng et al, 
1995) and, more recently, the catalytic protein subunit (Nakamura et al., 1997) of human 
telomerase opens up the prospects of developing new in situ assays for the detection and 
detailed localization of these critical enzyme components.  These new tools will provide 
information on the important issues of the tissue localization and regulation of this 
enzyme.   
The first objective of the present study was to analyze telomerase activity and 
telomere lengths throughout ViaCell’s entire amplification protocol.  We show that 
telomerase activity differs throughout their procedure.  Low telomerase activity was 
detected early in ViaCell’s process, that is, in ‘Pre-Freeze’ (Day-0), ‘Post-Thaw’, and 
‘Pre-Sep-1’ fractions.  This data is as expected.  Day-0 cells theoretically represent 
quiescent cells, so our data support the findings of Lansdorp et al (1996) and Engelhardt 
et al (1997) that quiescent cells are low in telomerase activity.  Telomerase activity was 
found to be significantly upregulated on cell proliferation and expansion stimulated with 
a proliferation-inducing cytokine combination in Pre-Sep-2, and decreased upon further 
proliferation and differentiation in Day-14 cells.    These results are in line with others 
(Engelhardt et al., 1997; Holt et al., 1996a) who showed that telomerase is upregulated in 
rapidly expanding cells, and downregulated upon differentiation.  Moreover, Day 14 cells 
were observed to have shorter telomere lengths (avg. 9 Kb) compared to Day-0 cells 
(avg. 10 Kb).   These results agree with previous studies by Engelhardt et al (1997) and 
Chiu et al (1996) that telomere lengths shorten upon cell proliferation and differentiation.  
Despite the presence of significant telomerase activity, we observed a proliferation-
associated telomeric DNA loss of about 1 Kb in Day-14 cell populations during the two 
weeks of ex vivo expansion compared to Day-0.  Thus, our data suggest that telomerase 
 59
activity in hematopoietic cells reduces, but does not prevent, telomere shortening on 
proliferation. 
 The next goal was to specifically test our first hypothesis that telomerase activity 
and telomere lengths (markers of the cellular proliferation and long-term reconstitution 
potential) appear to increase upon removal of differentiated Lin+ cells.  We observed a 
significant increase in telomerase activity in post-column separation cell populations 
(Post-Sep-1 and Post-Sep-2) compared to their pre-column equivalents.  Moreover, 
consistent with high telomerase activity in Post-Sep cells, we observed long telomeres in 
Post-Sep-1 (avg. 12 Kb) and Post-Sep-2 (avg. 14 Kb) compared to Pre-Sep-1 (avg. 10 
Kb).  We believe that this could be because the Post-Sep cell populations were enriched 
with HSCs and primitive progenitor cells known to be high in telomerase activity, after 
removal of differentiated Lin+ cells that are known to be low in telomerase activity.  To 
test this, we analyzed Lin+ cells from the sep-1 process.  We observed low telomerase 
activity in Lin+ cells off the column and short telomere lengths (avg. 7.5 Kb) in these 
differentiated cell populations.  These results support those of (Engelhardt et al., 1997) 
who showed that differentiated hematopoietic cells contain low to undetectable 
telomerase activity and short telomere lengths.  These results support our hypothesis that 
removal of telomerase-low telomere-short Lin+ cells appears to increase telomerase 
activity and telomere lengths in the remaining cells.  Although it is possible that our 
observed telomerase increase could be due to the removal of Lin+ cells that had been 
secreting a repressing lymphokine that reduced telomerase activity in the pre-sep-1 cells, 
we believe this is unlikely since very little time elapsed following removal of the lin+ 
cells (perhaps 30 minutes), thus the cells would have very little time in which to 
upregulate telomerase activity.  Our proposed mechanism remains the simplest 
explanation. 
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We then tested our second hypothesis that telomerase activity and telomere 
lengths decrease upon hematopoietic cell differentiation and proliferation.  We observed 
that telomerase activity decreased in Day-14 cells (expanded and differentiated 14 days) 
relative to Post-Sep-2 (selected 7 days).  Day 14 cells exhibited shorter telomere lengths  
(avg. 9 Kb) compared to Post-Sep-2 cells (avg. 14 Kb).  This is in line with findings of 
Counter et al (1995), Hiyama et al (1995), and Zhang et al (1996) who showed that upon 
cell differentiation, telomerase activity is repressed and telomere lengths are shortened. 
Moreover, significantly low telomerase activity was detected in Pre-Sep-3 cells (upon 
ATRA treatment) indicating that telomerase activity is repressed in terminally 
differentiated cells.  Thus our data supports Holt et al (1996a) who showed low 
telomerase activity in terminally differentiated cells.  These results support our second 
hypothesis that telomerase activity and telomere lengths decrease upon hematopoietic cell 
differentiation and proliferation.      
   Our data supports that of Chiu et al (1996) who showed that the presence of 
telomerase activity in hematopoietic subpopulations is insufficient to overcome the net 
telomere loss in the total population.  We speculate that a threshold level of telomerase 
activity may be required to maintain telomere lengths in a population of cells challenged 
mitotically.  Currently available technology does not allow us to determine whether our 
observed telomerase expression in ViaCell’s Day-14 cells functioned to slow the rate of 
telomere loss.  
The possibility that telomerase activity detected in ViaCell’s cell extracts does not 
correlate with its functional activity in the intact cells cannot be ruled out.  For instance, 
telomere-binding proteins (Zhong et al., 1992; McKay and Cooke, 1992; Cardenas et al., 
1993) or chromatin structures may play a role in regulating the accessibility of telomeres 
to the telomerase enzyme.  Moreover, telomerase activity might be expressed in only a 
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small subpopulation of cells (for example, CD34+KDR+ or CD34+CD71+, etc.), and 
stabilization of telomere length in this subpopulation could be masked when the cultures 
are analyzed as a whole.  If there exists a subpopulation of cells that maintains stable 
telomeres, and does not differentiate, it should theoretically have an unlimited replicative 
capacity.  Unfortunately since ViaCell does not positively select for CD34+ cells in any 
of their procedures, we were unable to analyze telomerase activity and telomere lengths 
in this specific fraction.  Given that there are currently no in vitro growth conditions in 
which primitive hematopoietic cells can selectively self-renew, the presence of such a 
population would not be easily identified (Chiu et al., 1996).  Eventually, only the use of 
single cell assays for telomerase activity, and more sensitive techniques for telomere 
length measurements, could help to resolve this issue.   
Recent studies have suggested that HSC activity exists within the murine and 
human Lin-CD34- population (Sato et al., 1999; Ando et al., 2000; Tajima et al., 2000; 
2001; Ogawa, 2002).  This redirects us to consider which cell population to select for 
therapeutic applications.  If HSCs exist within the CD34- population, the enrichment of 
CD34+ cells, the current practice in stem cell transplantation and to date one of the most 
efficient and effective HSC separation methods, may be of concern, since this may result 
in the loss of at least a portion of HSCs.  Hence, ViaCell believes that their process of 
isolating HSCs by removing only those cells (Lin+) known not to be HSCs is superior to 
the standard art of CD34 positive selection since it leaves intact a mixed population of 
cells that include HSCs, even if they are biochemically uncharacterized.  Although this 
process strongly enriches functional HCSs, these primitive cell populations remain 
biochemically uncharacterized.  Therefore, HSCs will need further extensive 
investigation to conclusively answer this question: what constitutes a HSC? 
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 Based on the positive selection of CD34 cells as current standard art, our next aim 
was to determine if telomerase activity and telomere lengths in ViaCell’s hematopoietic 
cell fractions correlate with the CD34+CD38- content.  Our data shows that telomerase 
activity and telomere lengths do not directly correlate with the CD34+CD38- content.  So 
indeed telomerase activity in ViaCell’s samples may reside, in part, elsewhere.  Although 
telomere lengths did not correlate with CD34+CD38- content, they did show some 
correlation with telomerase activity.   Thus, our data supports that of others (Shay, 1995; 
Holt et al., 1996a; Engelhardt et al., 1997) that telomerase is responsible for elongation 
and stabilization of telomere lengths in hematopoietic cells.  We speculate that there exits 
a subpopulation of hematopoietic cells other than CD34+CD38- that accounts for some of 
the telomerase activity.  Such candidates might include CD34- cells, early progenitors 
CD34+CD38+, CD34+CD71+, CD34+KDR+, and other hematopoietic stem/ progenitor 
cell fractions. Future experiments could include sorting the fresh cord blood, and the cell 
fractions stimulated to proliferate and differentiate, and specifically determining which 
hematopoietic cell subpopulations are low or high in telomerase.  The telomerase 
experiments could also be expanded by conducting Northern blots or RT-PCR for 
telomerase RNA, or alternatively by performing western blots using antibodies against 
the reverse transcriptase subunit.  Moreover, alternative methods of telomere length 
measurement, for example, “telomere amount and length assay” (TALA, Gan et al., 
2001) that are less labor intensive than the TLA could be tested.  Although TALA is not 
commercially available yet, is claimed to show a 4-fold greater sensitivity, >2 fold-higher 
reproducibility and 4-fold less time requirement (Gan et al., 2001).   
In summary, our data indicates that ViaCell’s removal of telomerase-low 
differentiated (Lin+) cells with short telomeres appears to increase the telomerase activity 
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and telomere lengths in the remaining cell population.  Also telomerase activity and 
telomere lengths decrease upon hematopoietic cell differentiation and proliferation.  
Lastly, we show that telomerase activity and average telomere length do not directly 
correlate with the CD34+CD38- content. 
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